HEALTH

NACDS to IRS: Delay health debit card changes

BY Michael Johnsen

ALEXANDRIA, Va. The National Association of Chain Drug Stores on Tuesday released a letter addressed to the Internal Revenue Service requesting clarifications of provisions regarding over-the-counter and prescription medications in the Patient Protection and Affordable Care Act.

First and foremost, NACDS is concerned that current IRS guidance would prohibit the use of debit cards in the purchase of not only any prescribed OTC medicine, but also any prescription-only therapy.

“Currently, there is no robust interaction between pharmacy dispensing systems and [inventory information approval systems; the systems used to substantiate purchases for flexible spending accounts]; an IIAS cannot distinguish between a medication for which a prescription is required and an OTC that has been prescribed,” NACDS explained. “As a result, a prohibition on using debit cards for prescribed OTC medications could have the practical effect of prohibiting the use of debit cards for all prescribed medications. … IRS’ prohibition on using debit cards for prescribed OTC medications greatly diminishes the value of the IIAS infrastructure unless pharmacies invest even more capital to modify the IIAS infrastructure to comply with the new guidance.”

There is significant capital at stake, NACDS argued, as the IIAS modifications to distinguish prescription-only and OTC across all stakeholders could take as long as two years to implement. NACDS requested IRS allow the use of debit cards to purchase prescribed OTCs; otherwise, the association requested that the two-week delay the IRS has allowed for implementation be extended by two years.

For a full copy of the letter, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Mission Skincare gets MLB endorsement for muscle rub analgesic

BY Michael Johnsen

NEW YORK Mission Skincare on Monday announced a new licensing agreement with Major Leagure Baseball Properties around its external analgesic Mission maximum-strength muscle rub.

“The muscle rub market has lacked innovation for some time now, and we decided it was time to ‘change the game’ — again,” stated Mission president Josh Shaw. “Everything from the Arnica extract to the vanishing-scent menthol, and the roll-on ‘no-mess’ applicator to the travel-friendly-sized tube was deliberately designed for athletes and people who lead active lifestyles.”

 

“I’m excited to see this come together, especially since I’m an integral part of both organizations,” stated David Wright, New York Mets third baseman and one of the professional athlete co-founders of Mission. “Just like stretching after competition or even a workout, caring for muscles is essential to staying in shape and getting in the game to perform the next day.”

 

 

Added Howard Smith, SVP licensing at MLB, “Giving our players a recovery product is important. Our relationship with Mission will give our players additional tools to help protect them as they play, and support them as they recover to prepare for the next game.”

 

Mission’s new rub is available at Dick’s Sporting Goods, GNC and CVS/pharmacy.

 

In addition to Wright, Mission was founded in 2008 by professional athletes, including tennis great Serena Williams, Phoenix Suns’ Steve Nash, soccer phenom Mia Hamm, Olympic swimmer Amanda Beard and golfer Sergio Garcia.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Botox approved for migraines

BY Alaric DeArment

SILVER SPRING, Md. A popular beauty treatment has won approval as a medical treatment as well.

 

The Food and Drug Administration announced Friday the approval of Allergan’s Botox (onabotulinumtoxinA) for preventing headaches in adult patients with chronic migraine.

 

 

“Chronic migraine is one of the most disabling forms of headache,” FDA division of neurology products director Russell Katz said. “Patients with chronic migraine experience a headache more than 14 days of the month. This condition can greatly affect family, work and social life, so it’s important to have a variety of effective treatments available.”

 

keyboard_arrow_downCOMMENTS

Leave a Reply

D.CALABRESE says:
Sep-02-2013 09:43 pm

Can you please share what are the chemicals or ingredients used with this botox treatment? Surely they have included something on it that will help cure and prevent chronic migraine. Also, please include what are the suggested ages for a person to have this treatment. I’d also ask my friend from colleyville botox about it. Wish to get the important information from this treatment.

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?